Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.78 |
| ▸ | EDNRB | P24530 | 19/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | TSPO | P30536 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23876322 | 0.95 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL18330569 | 0.94 | EDNRA (0.81) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569100 | 0.90 | EDNRA (0.64) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL8267995 | 0.90 | EDNRA (0.71) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL18929786 | 0.89 | EDNRA (0.63) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Macitentan SCHEMBL29378853 | 0.88 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL16135263 | 0.88 | EDNRA (0.76) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Macitentan SCHEMBL1445625 | 0.88 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL22516164 | 0.88 | EDNRA (0.69) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL18833088 | 0.87 | EDNRA (0.75) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143680-A | Preparation method of macitentan impurity B | 河北科技大学 | 2024-12-17 | — | — | CN | claimed |
| CN-119143680-A | Preparation method of macitentan impurity B | 河北科技大学 | 2024-12-17 | — | — | CN | disclosed |
| CN-119143680-A | Preparation method of macitentan impurity B | 河北科技大学 | 2024-12-17 | — | — | CN | disclosed |
| US-11667610-B2 | Method for preparing Macitentan and intermediate compound thereof | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667610-B2 | Method for preparing Macitentan and intermediate compound thereof | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11649216-B2 | Method for preparing Macitentan and intermediate compound thereof | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649216-B2 | Method for preparing Macitentan and intermediate compound thereof | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210300880-A1 | METHOD FOR PREPARING MACITENTAN AND INTERMEDIATE COMPOUND THEREOF | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2020201479-A1 | MACITENTAN FOR USE IN TREATING PORTOPULMONARY HYPERTENSION | ACTELION PHARMACEUTICALS LTD (CH) | 2020-10-08 | — | — | WO | disclosed |
| US-10669264-B2 | Process for the preparation of macitentan | LAURUS LABS LIMITED (IN) | 2020-06-02 | — | — | US | disclosed |
| EP-3019479-A1 | PROCESS FOR PREPARING A PYRIMIDINE INTERMEDIATE | Actelion Pharmaceuticals Ltd. (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-20160052891-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-25 | — | — | US | disclosed |
| US-20160052891-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-25 | — | — | US | disclosed |
| US-20160052891-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-25 | — | — | US | disclosed |
| EP-2978746-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | Actelion Pharmaceuticals Ltd. (CH) | 2016-02-03 | — | — | EP | disclosed |
| WO-2015004265-A1 | PROCESS FOR PREPARING A PYRIMIDINE INTERMEDIATE | ACTELION PHARMACEUTICALS LTD (CH) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004265-A1 | PROCESS FOR PREPARING A PYRIMIDINE INTERMEDIATE | ACTELION PHARMACEUTICALS LTD (CH) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014155304-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014155304-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2010144477-A2 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669264-B2 | Process for the preparation of macitentan | MACO1, MLEC, MPST | EDNRA 3404/4885EDNRB 4041/4885SLC6A2 721/4885 |
| US-11649216-B2 | Method for preparing Macitentan and intermediate compound thereof | TPMT, NUDT1, DHPS | EDNRA 4090/4885EDNRB 3570/4885SLC6A2 1379/4885 |
| US-11667610-B2 | Method for preparing Macitentan and intermediate compound thereof | TPMT, NUDT1, DHPS | EDNRA 4090/4885EDNRB 3570/4885SLC6A2 1379/4885 |
| US-20210300880-A1 | METHOD FOR PREPARING MACITENTAN AND INTERMEDIATE COMPOUND THEREOF | TPMT, NUDT1, DPYD | EDNRA 4202/4885EDNRB 3659/4885SLC6A2 1646/4885 |
| US-20160052891-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | DPYD, TYMS, TYMP | EDNRA 4008/4885EDNRB 3896/4885SLC6A2 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.